Pharmacokinetic study of enrofloxacin in Nile tilapia (Oreochromis niloticus) after a single oral administration in medicated feed.
The objective of this study was to evaluate the disposition kinetics of enrofloxacin (ENR) in the plasma and its distribution in the muscle tissue of Nile tilapia (Oreochromis niloticus) after a single oral dose of 10 mg/kg body weight via medicated feed. The fish were kept at a temperature between 28 and 30 °C. The collection period was between 30 min and 120 h after administration of the drug. The samples were analyzed by high-performance liquid chromatography with a fluorescence detector (HPLC-FLD). The ENR was slowly absorbed and eliminated from the plasma (Cmax = 1.24 ± 0.37 μg/mL; Tmax = 8 h; T1/2Ke  = 19.36 h). ENR was efficiently distributed in the muscle tissue and reached maximum values (2.17 ± 0.74 μg/g) after 8 h. Its metabolite, ciprofloxacin (CIP), was detected and quantified in the plasma (0.004 ± 0.005 μg/mL) and muscle (0.01 ± 0.011 μg/g) for up to 48 h. After oral administration, the mean concentration of ENR in the plasma was well above the minimum inhibitory concentrations (MIC50 ) for most bacteria already isolated from fish except for Streptococcus spp. This way the dose used in this study allowed for concentrations in the blood to treat the diseases of tilapia.
Department of Food Science, School of Food Engineering, University of Campinas, Campinas, São Paulo, Brazil.
J A
JA
Teles
Department of Food Science, School of Food Engineering, University of Campinas, Campinas, São Paulo, Brazil.
L C
LC
Castello Branco
Department of Food Science, School of Food Engineering, University of Campinas, Campinas, São Paulo, Brazil.
M
M
Del Bianchi
Aquaculture Center of São Paulo State University (CAUNESP), Jaboticabal, São Paulo, Brazil.
F
F
Pilarski
Department of Food Science, School of Food Engineering, University of Campinas, Campinas, São Paulo, Brazil.
F G R
FG
Reyes
D000284:Administration, Oral; D000821:Animal Feed / Q000032:analysis*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D023681:Cichlids / Q000097:blood* / Q000378:metabolism; D002939:Ciprofloxacin / Q000097:blood / Q000378:metabolism; D000077422:Enrofloxacin; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D018482:Muscle, Skeletal / Q000737:chemistry
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077422:Enrofloxacin; D002939:Ciprofloxacin